2019 James & Wells Innovation Award along with MTANZ Manufacturing/Export Winners

Teleflex Medical (Innovation) and Enztec (Manufacturing & Export) Winners Announced

A minimally invasive treatment for men with benign prostatic hyperplasia (BPH) has won the James & Wells Medical Technology Association of New Zealand (MTANZ) Innovation Award for 2019.

Teleflex Medical received the award for its UroLift ® System from Jonathan Lucas, partner at James & Wells, at the Health Tech Week Gala Dinner last night (July 2). ENZTEC was also named as the winner of the James & Wells MTANZ Manufacturing and Export Award for its Ligament Tensioner at the awards last night. The awards are open to both imported and locally-developed medical devices. 

“Medical devices available to NZ patients and clinicians are among the best in the world, as shown by these innovative devices. Our members constantly strive to be innovative to deliver better outcomes for patients and enable us to be highly competitive on the world market,” says MTANZ chief executive Faye Sumner, CNZM. 

BPH, also known as an enlarged prostate, is a common condition marked by bothersome urinary symptoms that can cause loss of productivity , depression, interrupted sleep and decreased quality of life.1 More than 40 percent of men in their 50s have BPH and more than 80 percent of men in their 70s have BPH.  If left untreated, the condition can worsen over time and cause permanent bladder damage.2

Before UroLift, men had three pathways for treatment: Watch/Wait, medication or tissue destructive surgery. 

The UroLift System is a minimally invasive approach that shows symptom relief significantly better than medication with a risk profile better than surgery. It is the only treatment with no new, sustained erectile or ejaculatory dysfunction and is a simple and straight forward procedure offering a better patient experience. The device may be permanently implanted in a transurethral outpatient procedure. 
UroLift reduces the overall cost to the health system by shortening overnight hospital stays associated with traditional surgical interventions.
The judging panel said of Urolift, “An innovative alternative to conventional methods of treating benign enlarged prostate issues with little side effects and no drugs.”
Meanwhile, Christchurch-based Enztec’s won an award for its ‘X-Wing’ ligament tensioner, an instrument system which enables pre-tensioning of a hamstring tendon graft during anterior cruciate ligament (ACL) reconstruction surgery. This instrument was designed, manufactured and evaluated in New Zealand. It is distributed by Smith & Nephew, and has been successfully launched into Australasia. 
The Enztec product was showcased at the world’s largest US orthopaedic convention in March 2019 - preparations are well underway to launch this technology into the US market.